medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2013, Número 2

<< Anterior

Rev Invest Clin 2013; 65 (2)


Epidemiología de la osteoporosis en México. Dirección presente y futura

Clark P, Tamayo JA, Cisneros F, Rivera FC, Valdés M

Idioma: Ingles.
Referencias bibliográficas: 46
Paginas: 183-191
Archivo PDF: 157.61 Kb.


RESUMEN

El presente artículo define la postura y recomendaciones de un grupo multidisciplinario de expertos de la Coordinación de los Institutos Nacionales de Salud de México en relación con la osteoporosis como un problema de salud pública creciente en el país. Para esta publicación se realizó la revisión de la evidencia científica de los datos de impacto de esta enfermedad, así como de los recursos de diagnóstico y tratamiento disponibles. Ofrece recomendaciones para futuras investigaciones en el área que permitirán llenar huecos del conocimiento actual para un mejor entendimiento de los factores de riesgo, prevención y tratamiento de esta entidad que apoyen de forma sustancial la optimización de los recursos de la investigación y asistencia y sirvan de marco referencial para epidemiólogos, tomadores de decisiones y autoridades en el diseño de futuros programas de salud enfocados a la osteoporosis y sus complicaciones.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997; 7(5): 407-13.

  2. CONAPO. http://www.conapo.gob.mx/index.php? option=com_c ontent&view=article&id=36&Itemid=234; 2009.

  3. Anuario Estadístico de los Estados Unidos Mexicanos. 2010. Disponible en: www.inegi.org.mx

  4. Frenk J, Sepulveda J, Gomez-Dantes O, Knaul F. Evidence-based health policy: three generations of reform in Mexico. Lancet 2003; 362(9396): 1667-71.

  5. Gobierno Federal. Quinto Informe de Gobierno. http://quinto.informe.gob.mx/ y http://www.segurop opular. salud. gob. mx/images/contenidos/Causes/catalogo_2010.pdf [Accessed June 06, 2012].

  6. Reza A, Vergara L, Mendoza Z, et al. Osteoporosis. Posición de la Sociedad Mexicana de Nutrición y Endocrinología. Rev Endocrino y Nutr 2004; 12(3): 123-63.

  7. AMMOM. Consenso Mexicano de Osteoporosis. Rev Invest Clin 2001; 53(5): 469-95.

  8. Gobierno del Estado de Guanajuato. Normas. 2012. Disponible en: www.guanajuato.gob.mx/ssg/prescripcion/normas/ 035SSA202.pdf

  9. Johansson H, Clark P, Carlos F, Oden A, McCloskey EV, Kanis JA. Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican institute of social security. Osteoporos Int 2011; 22(8): 2359-64.

  10. Clark P, Carlos F, Vázquez-Martínez J. Epidemiology, costs and burden of osteoporosis in Mexico. Arch Osteoporosis 2010.

  11. Clark P, Lavielle P, Franco-Marina F, et al. Incidence rates and life-time risk of hip fractures in Mexicans over 50 years of age: a population-based study. Osteoporos Int 2005; 16(12): 2025-30.

  12. Bacon WE, Maggi S, Looker A, et al. International comparison of hip fracture rates in 1988-89. Osteoporos Int 1996; 6(1): 69-75.

  13. Clark P, Cons-Molina F, Deleze M, et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int 2009; 20(2): 275-82.

  14. Clark P, Cons-Molina F, Deleze M, Talavera JO, Palermo L, Cummings SO. The prevalence of radiographic vertebral fractures in Mexican men. Osteoporos Int 2009.

  15. Deleze M, Cons-Molina F, Villa AR, et al. Geographic differences in bone mineral density of Mexican women. Osteoporos Int 2000; 11(7): 562-9.

  16. Clark P, Ragi S, Delezé M, Mühlen Dv, Barrett-Connor E. The prevalence of low bone mineral density in a random sample of Mexican women and men 50 years and older. A population study. J Clin Densitom 2006; 9(2): 234-234.

  17. Kanis JA on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at theprimary health-care level. Thechical Report. World Health Organization Collaborating Centre for Metabolic Bone diseases, University of Sheffield, UK. 2007 [Printed by the University of Sheffield].

  18. Lorrain J, Paiement G, Chevrier N, et al. Population demographics and socioeconomic impact of osteoporotic fractures in Canada. Menopause 2003; 10(3): 228-34.

  19. Lips P, van Schoor NM. Quality of life in patients with osteoporosis. Osteoporos Int 2005; 16(5): 447-55.

  20. Rabenda V, Manette C, Lemmens R, Mariani AM, Struvay N, Reginster JY. Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clin Exp Res 2007; 19(1): 55-60.

  21. Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 1997; 103(2A): 20S-25S; discussion 25S-26S.

  22. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy 2006; 77(1): 51-63.

  23. Clark P, Carlos F, Barrera C, et al. Direct costs of osteoporosis and hip fracture: an analysis for the Mexican healthcare system. Osteoporos Int 2008; 19(3): 269-76.

  24. Carlos F, Clark P, Maciel H, Tamayo JA. Direct costs of osteoporosis and hip fracture: an analysis for the Mexican Social Insurance Health Care System. Sal Pub Mex 2009; 51(Suppl. 1): S108-S113.

  25. Velasco-Murillo V, Navarrete-Hernández E, Pozos-Cavanzo JL, Ojeda-Mijares RI, Camacho-Rodriguez Mde L. Fractures in postmenopausal women in the IMSS: frequency and costs of hospital care. Gac Med Mex 2003; 139(5): 453-8.

  26. Zambrana M, Zurita B, Ramírez TdJ, Coria I. Gasto hospitalario de cinco patologías de alto impacto económico. Rev Med Inst Mex Seguro Soc 2008; 46(1): 43-50.

  27. Cruz G, Cisneros D, Salazar P, Tejeida L. Costos institucionales y dificultades en la atención de los pacientes con fracturas por osteoporosis. Acta Ortop Mex 2002; 16(6): 292-5.

  28. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, et al. Costeffective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int; 2008; 19(4): 437-47.

  29. McClung M. The clinical and epidemiologic consequences of redefining treatment criteria: who should be treated? Sal Pub Mex 2009; 51(Suppl. 1): S46-S51.

  30. Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 2006; 17(10): 1459-71.

  31. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 2008; 19(10): 1395-408.

  32. Goeree R, Blackhouse G, Adachi J. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Curr Med Res Opin 2006; 22(7): 1425-36.

  33. Fleurence RL, Iglesias CP, Johnson JM. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics 2007; 25(11): 913-33.

  34. Seeman E, Eisman JA. 7: Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual’s absolute risk of fracture. Med J Aust 2004; 180(6): 298-303.

  35. Tosteson AN, Burge RT, Marshall DA, Lindsay R. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care 2008; 14(9): 605-15.

  36. Fujiwara S, Nakamura T, Orimo H, et al. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 2008; 19(4): 429-35.

  37. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005; 16(3): 229-38.

  38. Arden NK, Baker J, Hogg C, Baan K, Spector TD. The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: a study of postmenopausal twins. J Bone Miner Res 1996; 11(4): 530-4.

  39. Slemenda CW, Turner CH, Peacock M, et al. The genetics of proximal femur geometry, distribution of bone mass and bone mineral density. Osteoporos Int 1996; 6(2): 178-82.

  40. Johnston CC Jr., Slemenda CW. Determinants of peak bone mass. Osteoporos Int 1993; 3(Suppl. 1): 54-5.

  41. Duncan EL, Brown MA. Clinical review 2: Genetic determinants of bone density and fracture risk-state of the art and future directions. J Clin Endocrinol Metab; 2010, 95(6): 2576-87.

  42. Magana JJ, Gómez R, Cisneros B, et al. Association of the CT gene (CA) polymorphism with BMD in osteoporotic Mexican women. Clin Genet 2006; 70(5): 402-08.

  43. Magana JJ, Gómez R, Cisneros B, Casas L, Valdes-Flores M. Association of interleukin-6 gene polymorphisms with bone mineral density in Mexican women. Arch Med Res 2008; 39(6): 618-24.

  44. Falcon-Ramirez E, Casas-Avila L, Miranda A, et al. Sp1 polymorphism in collagen I alpha1 gene is associated with osteoporosis in lumbar spine of Mexican women. Mol Biol Rep; 38(5): 2987-92.

  45. Clark P, De la Pena F, Gomez Garcia F, Orozco JA, Tugwell P. Risk factors for osteoporotic hip fractures in Mexicans. Arch Med Res 1998; 29(3): 253-7.

  46. Vivanco-Muñoz N, Reyes-Sánchez M, Lazcano E, Díaz R, Antúnez O, Clark P. Physical activity is a prognostic factor for bone mineral density in Mexican children. Bol Med Hosp Infant Mex 2012; 69(1): 40-5.




2020     |     www.medigraphic.com